ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

ClinicalTrials.gov ID: NCT04493853

Public ClinicalTrials.gov record NCT04493853. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.

Study identification

NCT ID
NCT04493853
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
1,012 participants

Conditions and interventions

Interventions

  • Abiraterone Acetate Drug
  • Capivasertib Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 12, 2020
Primary completion
Oct 6, 2024
Completion
Mar 30, 2027
Last update posted
May 4, 2026

2020 – 2027

United States locations

U.S. sites
33
U.S. states
18
U.S. cities
32
Facility City State ZIP Site status
Research Site Tucson Arizona 85723
Research Site Tucson Arizona 85741
Research Site La Jolla California 92037
Research Site Orange California 92868
Research Site San Diego California 92123
Research Site Denver Colorado 80211
Research Site Lakewood Colorado 80215
Research Site Norwich Connecticut 06360
Research Site Fort Myers Florida 33901-8101
Research Site West Palm Beach Florida 33401
Research Site Chicago Illinois 60637
Research Site Geneva Illinois 60134
Research Site Lisle Illinois 60532
Research Site Baltimore Maryland 21201
Research Site Detroit Michigan 48201
Research Site Grand Rapids Michigan 49503
Research Site Troy Michigan 48084
Research Site Syracuse New York 13210
Research Site The Bronx New York 10461
Research Site Asheville North Carolina 28805
Research Site Durham North Carolina 27710
Research Site Columbus Ohio 43210
Research Site Lancaster Pennsylvania 17601
Research Site Philadelphia Pennsylvania 19111
Research Site Pittsburgh Pennsylvania 15232
Research Site Charleston South Carolina 29401
Research Site Myrtle Beach South Carolina 29572
Research Site Chattanooga Tennessee 37404
Research Site Houston Texas 77090
Research Site Norfolk Virginia 23502
Research Site Roanoke Virginia 24014
Research Site Seattle Washington 98104
Research Site Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 290 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04493853, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04493853 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →